| Literature DB >> 30646516 |
Maria Karadjian1, Christopher Essers2, Stefanos Tsitlakidis3, Bruno Reible4, Arash Moghaddam5,6, Aldo R Boccaccini7, Fabian Westhauser8.
Abstract
Standard treatment for bone defects is the biological reconstruction using autologous bone-a therapeutical approach that suffers from limitations such as the restricted amount of bone available for harvesting and the necessity for an additional intervention that is potentially followed by donor-site complications. Therefore, synthetic bone substitutes have been developed in order to reduce or even replace the usage of autologous bone as grafting material. This structured review focuses on the question whether calcium phosphates (CaPs) and bioactive glasses (BGs), both established bone substitute materials, show improved properties when combined in CaP/BG composites. It therefore summarizes the most recent experimental data in order to provide a better understanding of the biological properties in general and the osteogenic properties in particular of CaP/BG composite bone substitute materials. As a result, BGs seem to be beneficial for the osteogenic differentiation of precursor cell populations in-vitro when added to CaPs. Furthermore, the presence of BG supports integration of CaP/BG composites into bone in-vivo and enhances bone formation under certain circumstances.Entities:
Keywords: bioactive glass; bone substitutes; bone tissue engineering; calcium phosphate; composite bone substitute materials
Mesh:
Substances:
Year: 2019 PMID: 30646516 PMCID: PMC6359412 DOI: 10.3390/ijms20020305
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Studies included in the review.
| First Author | Ref. | Year | Composite | Percentage | Setup | Methods/Endpoints | Biological Outcome | ||
|---|---|---|---|---|---|---|---|---|---|
| 1st Phase | 2nd Phase | 1st Phase | 2nd Phase | ||||||
| Barbieri | [ | 2017 | HA/β-TCP 4/96 | AOC | 51.7 | 48.3 | in-vivo | Histomorphometry | Compared to CaP/AOC rarely any formation of new bone on CaP/BG composite. |
| β-TCP | 45S5 (45 wt% SiO2, 24.5 wt% CaO, 24.5 wt% Na2O, 6 wt% P2O5)-Collagen mix | 61.8 | 38.2 | ||||||
| Bellucci | [ | 2017 | HA | BG_Ca/Mix (47.3% SiO2, 45.6% CaO, 2.3% K2O, 2.3% Na2O, 2.6% P2O5) | 70/20/0 | 30/80/100 | in-vivo | X-Ray, histomorphometry | Increased osteoconductivity of pure BG scaffolds compared to composites, with best results for BG_Ca/Mix. |
| 45S5 | / | 100 | 0 | ||||||
| Chen | [ | 2017 | Si-Sr-Zn-Mg-codoped CaP | 45S5 | 100/6.7/0 | 0/93.3/100 | in-vitro | Cell proliferation, osteogenic differentiation, protein expression | Improved proliferation and differentiation of mesenchymal stem cells in composite materials. |
| Lopes | [ | 2016 | β-TCP | 45S5 | 100/95/92.5 | 0/5/7.5 | in-vitro | Cell viability, SEM | Increased cell viability and advanced attachment in 7.5%-composites. |
| Bellucci | [ | 2015 | HA | BG_Ca/Mix | 20/70 | 80/30 | in-vitro | Cell viability, cell proliferation, cytotoxicity | Cell viability in composites equivalent to 45S5-BG. |
| 45S5 | / | 100 | 0 | ||||||
| Lu | [ | 2015 | HA/β-TCP (40/60) | 58S (60% SiO2, 36% CaO, 4% P2O5) | n/s | n/s | in-vitro | Cell viability, osteogenic differentiation | Synergistic effect of BG and CaP on osteogenic differentiation, further enhanced by BMP-2. |
| HA/β-TCP (40/60) | / | 100 | 0 | ||||||
| Bernhardt | [ | 2013 | β-TCP | Na-Mg-Si-BG system | 96 | 4 | in-vitro | Cell adhesion, osteogenic differentiation, cell viability | Cell viability and number increased or equal for pure β-TCP vs. β-TCP/BG composites. |
| HA/β-TCP (60/40) | SiO2 matrix | n/s | n/s | ||||||
| HA | SiO2 matrix | 76 | 24 | ||||||
| β-TCP | / | 100 | 0 | ||||||
| Bellucci | [ | 2013 | HA | BG_Ca (47.3% SiO2, 45.6% CaO, 4.6% Na2O, 2.6% P2O5) | 80/60 | 20/40 | in-vitro | Cell adhesion, cell proliferation, cell viability, osteogenic differentiation | Increased osteogenic differentiation for BG_Ca composites (ALP activity) vs. 45S5-BG composites. |
| 45S5 | |||||||||
| Cholewa-Kowalska | [ | 2009 | HA | S2 (80% SiO2, 16% CaO, 4% P2O5) | 100/90/50/0 | 0/10/50/100 | in-vitro | Cell viability, osteogenic differentiation | Osteogenic differentiation (ALP activity) significantly improved for the 50:50 S2 composite. |
| A2 (40% SiO2, 54% CaO, 6% P2O5) | |||||||||
| Hesaraki | [ | 2009 | β-TCP | 64% SiO2, 26% CaO, 5% P2O5, 5% MgO | 90/75/60 | 10/25/40 | in-vitro | Cell viability | Improved cell viability in composite materials, regardless of BG content. |
| Yu | [ | 2009 | β-TCP | 62.04 wt% P2O5, 14.68 wt% CaO, 13 wt% MgO, 10.28 wt% Na2O | 100/80 | 0/20 | in-vivo | SEM, histomorphometry | No differences in in-vivo biocompatibility between pure β-TCP and composite material. |
| Kucukkol-basi | [ | 2009 | HA | 45S5 | 0/50/100 | 100/50/0 | in-vivo | Histomorphometry | No major differences between the composite and both pure HA and 45S5-BG. |
| Cai | [ | 2009 | β-TCP | 45 wt% P2O5, 22 wt% CaO, 25 wt% Na2O, 8 wt% MgO | 100/80 | 0/20 | in-vitro | SEM, cell count | BG addition increased cell number as well as attachment and distribution of cells. |
| Haimi | [ | 2009 | CaP (n/s) | Na2O, K2O, MgO, CaO, B2O3, TiO2, Ca2PO5, SiO2 | n/s | n/s | in-vitro | Cell adhesion, cell viability, cell proliferation, osteogenic differentiation | No remarkable differences between pure BG and CaP-coated BG. |
β-TCP: β-tricalcium phosphate, AOC: Alkylene oxide copolymer, n/s: not specified, % = mol% unless stated otherwise, wt% = percentage by weight. Methods = biological methods, SEM: scanning electron microscopy, ALP: alkaline phosphatase. When glass compositions are linked to names (e.g., 45S5) the exact composition is shown when mentioned first.
Figure 1In-vitro evaluation models. 2D culture allows physical contact, mostly with particles of the respective bone substitute, whilst cells seeded on scaffolds are cultivated in 3D culture conditions. The indirect culture setting allows evaluation of the dissolution products of the materials that underwent incubation in the respective medium for a certain amount of time before the particle-free medium is transferred to the cells (indicated by the black arrow).
In-vitro evaluation, study designs.
| First Author | Ref. | Cell Type | Species | Cell Number | Medium | Culture Time | Culture Setting |
|---|---|---|---|---|---|---|---|
| Chen | [ | rMSC/rOMSC | rat | 100,000/cm2 | MM + Osteogenic factors (β-GP + AA) | 21 d | indirect |
| Lopes | [ | MG 63 | human | 8000/well (96-well-plate) | MM | 3 d | direct |
| Bellucci | [ | BALB/3T3 + MLO-Y4 | mouse | n/s | MM | 24 h–48 h | direct and indirect |
| Lu | [ | ASC | human | 50,000/0.6 cm2/10,000/0.6 cm2 | MM | 14 d | direct |
| Bernhardt | [ | SaOS-2 | human | 160,000/0.1 2 cm3 | MM + Osteogenic factors (β-GP + AA) | 28 d | direct |
| Bellucci | [ | MC3T3-E1 | mouse | 50,000/g | GM + ODM (including β-GP + AA) | 21 d | direct |
| Cholewa-Kowalska | [ | hBMSC | human | 10,000/cm2 | MM + ODM (including DM + AA) | 7 d | direct |
| Hesaraki | [ | G-292 | human | 30,000/mL | MM | 7 d | direct |
| Cai | [ | MC3T3-E1 | mouse | 1,000,000/0.375 cm2 | MM | 14 d | direct |
| Haimi | [ | ASC | human | 500,000/0.98 cm2 | MM | 14 d | direct |
n/s: not specified, rMSC: rat bone marrow-derived mesenchymal stem cells, rOMSC: osteoporotic rat bone marrow-derived mesenchymal stem cells, MG 63: osteoblast-like cells, BALB/3T3: mouse embryonic fibroblast cell line, MLO-Y4: murine long bone osteocyte-like immortalized cell line, ASC: adipose tissue-derived mesenchymal stem cells, SaOS-2: osteoblast-like cells, hBMSC: human bone marrow stromal cells, G-292: human osteosarcoma cells, MC3T3-E1: mouse osteoblast precursor cell line, MM: maintenance medium, GM: growth medium, ODM: osteogenic differentiation medium, β-GP: β-glycerophosphate, AA: ascorbic acid, DM: dexamethasone. The cell number per sample refers either to the surface of the scaffold/the well (cells/cm2) or to the scaffold without further specification (arbitrary unit) or the volume of the medium (cells/mL). Culture time in days (d) or hours (h). If multiple cell numbers are indicated, different cell numbers were used for different assays within one study.
In-vivo evaluation designs.
| First Author | Ref. | Species | Location and Defect Size | Implantation Time | Methods | Parameter |
|---|---|---|---|---|---|---|
| Bellucci | [ | New Zealand Rabbit | Femur | 2 m | Post-mortem femur X-ray | Graft position |
| Histomorpho-metry | Implant-bone-interface: bone formation, bone healing/contact, cracks of the graft | |||||
| SEM | Bioactive bone bonding mechanism (confirmation of histology) HA-Layer | |||||
| EDS + microradiography | Dissolution kinetics | |||||
| Barbieri | [ | Mongrel dog | Orthotopic (spine) and ectopic (i.m.) (defect size n/s) | 3 m | Histomorpho-metry | Bone formation, bone-surface-contact, in-vivo resorption rate tissue response (i.m.) |
| Fluorescence microscopy | Bone development (calcein labeling) | |||||
| Yu | [ | New Zealand Rabbit | Femur (2 mm diameter, depth n/s) | 1/2/3/6 m | Histomorpho-metry | Bone formation, bone-implant-interface, resorption rates |
| SEM | Bone formation, bone-implant-interface, resorption rates | |||||
| Kucukkolbasi | [ | New Zealand Rabbit | Tibia (3 mm diameter, depth n/s) | 1/3/6 m | Histomorpho-metry | Bone formation, resorption rates, tissue reactions |
SEM: scanning electron microscopy, EDS: energy dispersion spectroscopy, HA: hydroxyapatite, i.m.: intramuscular. Implantation time in months (m).